Amyloidosis

Clinical Trials

Below is a list of Amyloidosis clinical trials from the clinical trials database at Mayo Clinic.

Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
PRIMARY OBJECTIVE: I. To assess the confirmed hematologic response rate (ACR + VGPR + PR) of the combination of bortezomib, cyclophosphamide and dexamethasone in patients with primary systemic amyloidosis. SECONDARY OBJECTIVES: I.
Read more

CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
OBJECTIVES: - To assess the response rate and duration of remission with low-dose CC-4047 plus dexamethasone in patients with relapsed or refractory multiple myeloma or amyloidosis. - To assess the toxicity of CC-4047 plus dexamethasone in this patient population.
Read more

Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis
The primary purpose of this study is to assess the efficacy and safety of treatment with Kiacta in adult patients with AA Amyloidosis.
Read more

Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
OBJECTIVES: Primary - Compare hematologic response rate in patients with primary systemic amyloidosis treated with conventional chemotherapy comprising low-dose melphalan and dexamethasone vs high-dose melphalan followed by autologous stem cell transplantation. - Compare the toxicity of these regimens in these patients.
Read more

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
OBJECTIVES: Primary - To compare hematologic overall response (partial response [PR], very good PR, amyloid complete hematologic response [ACR], and stringent complete response [sCR]) after 3 courses of therapy in patients with previously untreated systemic light-chain amyloidosis treated with melphalan and dexamethasone with vs without bortezomib.
Read more

Study of Oral MLN9708 in Adult Patients With Relapsed or Refractory Light Chain Amyloidosis
This study will include patients with previously treated systemic relapsed or refractory light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the safety profile and the maximum tolerated dose/recommended phase 2 dose of MLN9708 administered orally.
Read more